Stanker James H
Known title: Chief Financial OfficerCIK: 0001681718
Associated companies
Transaction History
| PCSA | ▲ Buy | Option Exercise | 644 | — | 7/10/2024 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 282 | $482 | 7/10/2024 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 1,675 | — | 4/5/2024 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 518 | $1K | 4/5/2024 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 1,675 | — | 1/1/2024 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 518 | $1K | 1/1/2024 | View on chart |
| PCSA | ▲ Buy | Grant | 15,000 | $5K | 10/12/2023 | View on chart |
| PCSA | ▲ Buy | Grant | 22,500 | $5K | 10/10/2023 | View on chart |
| PCSA | ▲ Buy | Grant | 12,500 | $10K | 2/9/2023 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 7,601 | — | 8/5/2022 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 2,462 | $8K | 8/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Processa Files Prospectus for 306.5M Share Offering
Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.
Processa Files Prospectus for 306.5M Share Offering. Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.